Wang @zach_wallace_md et al. Machine learning can accurately classify clinical note sections as reflecting a diagnosis of AAV. As a machine learning sceptic, data like this helps (slowly) convert me. @RheumNow #ACR22 Abstr#0700 https://t.co/qbq9j9XzXG https://t.co/8iNJElI2vJ

• Accurate Identification of ANCA-Associated Vasculitis Cases from Clinical Notes…

I typically do not use mepolizumab for "vasculitic" EGPA --> recent ACR/VF guidelines agreed Interesting study @TerrierBen suggests benefit regardless of ANCA, BVAS, VDI Have others been using in this context or seen similar? #ACR22 @RheumNow #ACRBest #1075 https://t.co/C6isdSn2eI

Are we really treating Psoriatic disease if we only address active disease domains and T2T? #ACR22 https://t.co/D3F5EzLfeP https://t.co/TO3GyZA6Lb

• https://bit.ly/3E4Q5SJ

#ACR22 Abstr#1654 Press Release #lupus. A cohort study using case-crossover design showed that HCQ dose =<5mg/kg actual body weight OR <400mg/day were associated with increased risk of severe #SLE flare requiring hospitalisation. Need to review Guidelines on HCQ dose @RheumNow https://t.co/5mMh7g6wcA

Toxic granules in blood vessels may damage vasculature and cause fibrosis around vessels. ‘Occult vascular disease occurs in #scleroderma, don’t forget about it’ says Wigley at Hench Memorial Lecture #ACR22 ⁦@RheumNow⁩ ⁦@ACRheum⁩ insights by a humble #SSc leader 🙏🏻 https://t.co/M82p6DwZ6Q

AURORA 2 data VOC-treated pts w/ pure and mixed Class V lupus nephritis saw reductions in UPCR that occurred faster than in those treated with MMF and low-dose steroids alone. Abs 0355 #ACR22 @RheumNow https://t.co/eHVLDCcti8 https://t.co/jbuiOSqqsa

• Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results …

Targeting MRI remission in RA, specifically targeting osteitis, did not confer benefit over clinical T2T over 2 years. Maybe our clinical examination is not so bad afterall @steverheum_hall @RheumNow ABST0890 #ACR22 https://t.co/8nUjWQONyk https://t.co/xGzZNLiJ7U

• Long Term Efficacy of a 2-year MRI Treat-to-target Treatment Strategy on Diseas…

Meng MA of risk of tapering MTX from combo with bDMARD/tsDMARD in RA in remission. RR 0.90 (95% CI 0.84, 0.97) for maintaining remission over maximum 18 months. Authors conclude little risk to stopping - I disagree 10% is >0. @RheumNow #ACR22 Abstr#0916 https://t.co/9lJXdeVmpg https://t.co/CEV29Mc8uW

• Should RA Patients with Controlled Disease Taper Methotrexate from Targeted The…

> 50% of SLE pts showed activation of all 3 complement pathways. The most frequent patterns were normal CL, low AL, normal MBL; low CL & AL, normal MBL. Dz activity, not damage, assoc'd only w/low CL and AL, and normal MBL. Abs 0317 #ACR22 @RheumNow https://t.co/nXtuZCfKDI

• Full Characterization of the Three Pathways of Complement System in Patients wi…

Leng et al. 52 week results tocilizumab biosimilar vs originator in RA. Shocker, it's the same. @RheumNow #ACR22 Abstr#0917 https://t.co/5JAoGBRzUi https://t.co/7zCUNcdzbp

• Fifty-two-week Results from a Phase 3, Randomized, Double-blind, Active-control…

Proliferative LN assoc'd w/ higher risk of IFTA progression, suggesting that glomerular damage is one of the major drivers of IFTA progression in SLE. Abs 0319 #ACR22 @RheumNow https://t.co/CgdXhDBk3e https://t.co/AOZ1DnH6Sk

• Factors Associated with Worsening Interstitial Fibrosis/Tubular Atrophy in Lupu…

Package insert for avacopan has a lot of monitoring requirements, including liver risk, but that seems to be relatively small (2 events per 100 pt-yrs vs pred). Other risks actually favorable as compared to pred How are others monitoring LFTs? #ACR22 @RheumNow #1077 https://t.co/VFHCpkQMWN

Kim et al. KOBIO study retention rates b/tsDMARDs in RA-ILD. Lower than in RA without ILD. Smoking (OR 5.2) steroids (OR 0.3) influence. JAKi>tocilizumab>abatacept>TNFi @RheumNow #ACR22 Abstr#0920 https://t.co/ht7IFP7VJe https://t.co/Ul93kcdP5N

• Retention Rate and Safety of Biologic or Targeted Synthetic Disease Modifying A…

#ACR22 Abstr#0823 A systematic review which included 36 case series/report showed pulmonary manifestations are common in #VEXAS 56%. Unclear if due to VEXAS or previous disease which was misclassified. Longitudinal study with accurate & timely diagnosis could help @RheumNow https://t.co/ZJvmK2FWrI

Differentiation in UCTD? Abs 0328 finds puffy fingers, abnormal nailfold changes & SSc specific antibodies most predictive for UCTD progression to SSc. Younger age, serositis, +anti-dsDNA antibodies important for progression to SLE. #ACR22 @RheumNow https://t.co/DWL3V3dbFg https://t.co/fYHPOPdzfq

• Predicting Progression from Undifferentiated to Definitive Connective Tissue Di…